Shared mechanism of teratogenicity of anti-angiogenic drugs identified in the chicken embryo model
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Shared mechanism of teratogenicity of anti-angiogenic drugs identified in the chicken embryo model
Authors
Keywords
-
Journal
Scientific Reports
Volume 6, Issue 1, Pages -
Publisher
Springer Nature
Online
2016-07-22
DOI
10.1038/srep30038
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Thalidomide-induced teratogenesis: History and mechanisms
- (2015) Neil Vargesson BIRTH DEFECTS RESEARCH PART C-EMBRYO TODAY-REVIEWS
- Targeted agents for cancer treatment during pregnancy
- (2015) Matteo Lambertini et al. CANCER TREATMENT REVIEWS
- Everolimus for patients with metastatic renal cell carcinoma refractory to anti-VEGF therapy: Results of a pooled analysis of non-interventional studies
- (2015) Laurence Albiges et al. EUROPEAN JOURNAL OF CANCER
- Intravitreal Anti-VEGF Injections in Pregnancy: Case Series and Review of Literature
- (2015) Silvio Polizzi et al. JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
- Anticancer Properties of a Novel Class of Tetrafluorinated Thalidomide Analogues
- (2015) S. L. Beedie et al. MOLECULAR CANCER THERAPEUTICS
- Effect of anti-vascular endothelial growth factor antibody during early fetal development in rats
- (2014) Ikbal Kaygusuz et al. Journal of Maternal-Fetal & Neonatal Medicine
- Comparison of effects of anti-angiogenic agents in the zebrafish efficacy–toxicity model for translational anti-angiogenic drug discovery
- (2014) Geetanjali Chimote et al. Drug Design Development and Therapy
- Recognition of the phenotype of thalidomide embryopathy in countries endemic for leprosy
- (2013) Fernanda S.L. Vianna et al. CLINICAL DYSMORPHOLOGY
- Angiogenesis and anti-angiogenic therapy in prostate cancer
- (2013) Deborah Mukherji et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Are monoclonal antibodies a safe treatment for cancer during pregnancy?
- (2013) Maria Anna Sarno et al. Immunotherapy
- Pomalidomide is nonteratogenic in chicken and zebrafish embryos and nonneurotoxic in vitro
- (2013) C. Mahony et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Vascular Normalization as a Therapeutic Strategy for Malignant and Nonmalignant Disease
- (2013) S. Goel et al. Cold Spring Harbor Perspectives in Medicine
- Embryo-Fetal Transfer of Bevacizumab (Avastin) in the Rat Over the Course of Gestation and the Impact of Neonatal Fc Receptor (FcRn) Binding
- (2012) Mitchell Thorn et al. BIRTH DEFECTS RESEARCH PART B-DEVELOPMENTAL AND REPRODUCTIVE TOXICOLOGY
- Anti-angiogenic treatment strategies for the therapy of endometriosis
- (2012) M.W. Laschke et al. HUMAN REPRODUCTION UPDATE
- Angiogenesis inhibitors in the treatment of prostate cancer
- (2010) Paul G Kluetz et al. EXPERT OPINION ON PHARMACOTHERAPY
- Thalidomide-induced limb defects: resolving a 50-year-old puzzle
- (2009) Neil Vargesson BIOESSAYS
- Evaluation of the safety and pharmacokinetics of the multi-targeted receptor tyrosine kinase inhibitor sunitinib during embryo-fetal development in rats and rabbits
- (2009) S. Patyna et al. BIRTH DEFECTS RESEARCH PART B-DEVELOPMENTAL AND REPRODUCTIVE TOXICOLOGY
- Vandetanib (ZD6474), a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor (VEGFR) and Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinases: Current Status and Future Directions
- (2009) A. Morabito et al. ONCOLOGIST
- Thalidomide induces limb defects by preventing angiogenic outgrowth during early limb formation
- (2009) C. Therapontos et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3
- (2008) D. D. Hu-Lowe et al. CLINICAL CANCER RESEARCH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started